KROS: Keros Therapeutics Inc
KROS exchange rate has changed by -4.36% for today. During the day, the instrument was traded at a low of 10.24 and at a high of 10.84.
Follow Keros Therapeutics Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
KROS News
- KROS Turns to Next Wave of TGF-Beta Muscle Therapies
- KROS Turns to Next Wave of TGF-Beta Muscle Therapies
- Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
- Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
- KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
- KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
- Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
- Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
- Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
- Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
- KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
- KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
- KROS Rinvatercept: What to Know Before DMD Phase II Starts
- Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
- Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
- KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
- KROS Stock: What to Know About Rinvatercept in DMD
- KROS: Is the Discount Book Value a Value Trap?
- Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
- Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
- Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
- Keros earnings missed by $0.16, revenue fell short of estimates
- Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
- Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Frequently Asked Questions
What is KROS stock price today?
Keros Therapeutics Inc stock is priced at 10.30 today. It trades within 10.24 - 10.84, yesterday's close was 10.77, and trading volume reached 370. The live price chart of KROS shows these updates.
Does Keros Therapeutics Inc stock pay dividends?
Keros Therapeutics Inc is currently valued at 10.30. Dividend policy depends on the company, while investors also watch -31.79% and USD. View the chart live to track KROS movements.
How to buy KROS stock?
You can buy Keros Therapeutics Inc shares at the current price of 10.30. Orders are usually placed near 10.30 or 10.60, while 370 and -4.45% show market activity. Follow KROS updates on the live chart today.
How to invest into KROS stock?
Investing in Keros Therapeutics Inc involves considering the yearly range 9.79 - 22.55 and current price 10.30. Many compare -7.79% and -49.36% before placing orders at 10.30 or 10.60. Explore the KROS price chart live with daily changes.
What are Keros Therapeutics Inc stock highest prices?
The highest price of Keros Therapeutics Inc in the past year was 22.55. Within 9.79 - 22.55, the stock fluctuated notably, and comparing with 10.77 helps spot resistance levels. Track Keros Therapeutics Inc performance using the live chart.
What are Keros Therapeutics Inc stock lowest prices?
The lowest price of Keros Therapeutics Inc (KROS) over the year was 9.79. Comparing it with the current 10.30 and 9.79 - 22.55 shows potential long-term entry points. Watch KROS moves on the chart live for more details.
When did KROS stock split?
Keros Therapeutics Inc has gone through stock splits historically. These changes are visible in , 10.77, and -31.79% after corporate actions.
- Previous Close
- 10.77
- Open
- 10.78
- Bid
- 10.30
- Ask
- 10.60
- Low
- 10.24
- High
- 10.84
- Volume
- 370
- Daily Change
- -4.36%
- Month Change
- -7.79%
- 6 Months Change
- -49.36%
- Year Change
- -31.79%
- Act
- Fcst
- Prev